Melanotan II
Melanocortin agonist for tanning, libido, and appetite research.
0.5 mg 3×/week maintenance
Key Benefits
stimulates UV-independent skin darkening via MC1R activation
MC3R/MC4R activation enhances arousal (parent of PT-141)
MC4R agonism reduces food intake
research tool for multiple receptor systems
Recommended Injection Sites
Optimal injection locations for Melanotan II based on its route (Subcutaneous injection) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
Preferred SubQ site.
Good alternative.
Rotate sites each injection.
- IV administration
Active Signaling Pathway
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 10mg vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
MT-II activates MC1R on melanocytes to stimulate melanin production (tanning), MC3R/MC4R in the hypothalamus for sexual arousal and appetite suppression, and MC5R for exocrine gland regulation. Its broad melanocortin receptor activity produces multiple simultaneous effects.
Clinical Context
Melanotan II was developed at the University of Arizona as a potential photoprotective agent. Its broad melanocortin activity makes it a versatile research tool for studying multiple physiological systems.
Research Highlights
- Shown to produce significant skin darkening without UV exposure in clinical trials
- Demonstrated erectile function improvement in men with psychogenic ED
- Appetite suppression via MC4R activation — potential obesity research application
- Parent compound of PT-141 (bremelanotide) — FDA-approved derivative
Storage & Reconstitution
Store at -20°C. Reconstitute with 2 mL bacteriostatic water → 5 mg/mL. Stable 4 weeks at 2–8°C. Protect from light.
Loading phase: 0.5 mg/day for 1–2 weeks. Maintenance: 0.5–1 mg 2–3×/week.